Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 2, 1996, Pages 143-147

  Sheen, I Shyan ^a   Liaw, Yun Fan ^a,b   Lin, Shi Ming ^a   Chu, Chia Ming ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b Department of Pathology   (Taiwan)

Author keywords

Chronic hepatitis; Prednisolone withdrawal; Rebound

Indexed keywords

ALPHA2A INTERFERON; LYMPHOBLAST INTERFERON; PREDNISOLONE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; VIRUS HEPATITIS;

EID: 0029878872     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00051.x     Document Type: Article

References (32)

1. Scullard GH, Smith CI, Merigan TC, Robison WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-91.
2. Sagneli E, Maio G, Felaco FM et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; ii: 395-7.
3. Villa E, Theodossi A, Portmann B et al. Reactivation of hepatitis B virus infection in two patients: Immunosuppressive studies of liver tissue. Gastroenterology 1981; 80: 1048-53.
4. Lau JYN, Bain VG, Smith HM, Alexander GJM, Williams R. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation 1992; 53: 894-8.
5. Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C. Effects of short-term, high-dose prednisolone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5: 8-12.
6. Yokosuda O, Omata M, Imazeki F et al. Combination of short-term prednisolone and adenine arabinoside in the treatment of chronic hepatitis B. A controlled study. Gastroenterology 1985; 89: 246-51.
7. Perrillo RP, Regenstein FG, Bodicky CJ, Canpbell CR, Sanders GE, Sunwoo YG. Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisolone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 1985; 88: 780-6.
8. Omata M, Uchiumi K. Combination of prednisolone withdrawal and antiviral agents (adenine arabinoside, interferon) in chronic hepatitis B. A long-term follow-up study. J. Hepatol. 1986; 3 (Suppl. 2): S65-9.
9. Itoh S, Matsuo S, Oda T, Marutani K, Sasaki K. Triiodothyronine level and triiodothyronine thyroxine ratio in HBeAg-positive chronic hepatitis patients treated with prednisolone withdrawal. Dig. Dis. Sci. 1990; 35: 1110-14.
10. Rakela J, Redeker AG, Weliky B. Effect of short-term prednisolone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 1983; 84: 956-60.
11. Weller IVD, Bassendine MF, Murray AK et al. Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut 1982; 23: 650-5.
12. Brissot P, Jacquelinet C, Jouanolle H et al. Short-term prednisolone followed by recombinant human-interferon alone or combined with adenine-arabinoside in chronic hepatitis B. A prospective and randomized trial. J. Hepatol. 1991; 12: 181-9.
13. Lee SD, Tong MJ, Wu JC, Lin HC, Tsai YT, Lo KJ. A randomized double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B. J. Hepatol. 1991; 12: 246-50.
14. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomized controlled trial. J. Hepatol. 1994; 20: 175-80.
15. Nair MPN, Schwanz SA. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J. Immunol. 1984; 132: 2876-82.
16. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6: 173-9.
17. Hirai N, Shimizu M, Morioka T et al. Activities of the interferon system in patients with HBsAg-positive chronic hepatitis B during short-term steroid withdrawal therapy. Liver 1988; 8: 138-45.
18. Buti M, Esteban R, Esteban JI, Gonzalea A, Guardia J. Severe hepatic failure after Ara-A/prednisolone for chronic type B hepatitis. Gastroenterology 1987; 92: 274-5.
19. Laskus T, Slusarczyk J, Cianciara J, Loch T. Exacerbation of chronic active hepatitis B after short-term corticosteroid therapy resulting in fatal liver failure. Am. J. Gastroenterol. 1990; 85: 1414-17.
20. Chien RN, Sheen IS, Chu CM, Liaw YF. Beneficial effect of prednisolone priming and the need of maintenance interferon therapy in patients with chronic hepatitis B. J. Hepatol. 1993; 18 (Suppl. 1): S24.
21. Liaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7: 1-3.
22. Sheen IS, Liaw YF, Tai DI et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89: 732-5.
23. Hoofnagle JH, Davis GL, Pappas C et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1986; 104: 12-17.
24. Kita H, Moriyama T, Kaneko T et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 1039-44.
25. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol. 1993; 151: 4189-99.
26. Koziel MJ, Dudley D, Afdhal N et al. Hepatitis C virus (HCV): Specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J. Virol. 1993; 67: 7522-32.
27. Liaw YF, Lee CS, Tsai SL et al. T cell-mediated autologous hepatoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995 (in press).
28. Cerny A, McHutchison JG, Pasquinelli C et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 1995; 95: 521-30.
29. Tsai SL, Liaw YF, Yeh CT, Chu CM, Kuo GC. Cellular immune response in patients with dual infection of hepatitis B and C viruses: Dominant role of hepatitis C virus. Hepatology 1995; 21: 908-12.
30. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: Relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273-9.
31. Fong TL, Valialuck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisolone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107; 196-9.
32. Liaw YF, Sheen IS, Lin SM, Chen TJ, Chu CM. Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 1993; 13: 46-50.